{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-007476","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.061141+00:00","generated_at":"2026-06-21T22:55:56.344230+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic Biosciences reports Q3 2022 net loss of $0.8M; cash of $13.8M","bullets":["Net loss for Q3 2022 was approximately $0.8 million.","R&D expenses fell 48.9% YoY to $0.4 million, reflecting shift from XCART to DNase platform.","G&A expenses decreased 8.7% to $863,000.","Cash and cash equivalents were $13.8 million at quarter-end; expected to fund operations and pipeline development.","DNase oncology platform advancing toward first-in-human study for pancreatic carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-007476","json":"https://secwatch.observer/filing/0001683168-22-007476.json","markdown":"https://secwatch.observer/filing/0001683168-22-007476.md","text":"https://secwatch.observer/filing/0001683168-22-007476.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822007476/0001683168-22-007476-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822007476/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:55:56.344230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4cff48da7d0718f055c439437b8fbb428d843ccc","claim":"Xenetic Biosciences, Inc. reported the three months ended September 30, 2022 results: net income approximately $0.8 million.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022 was approximately $0.8 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822007476/0001683168-22-007476-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"approximately $0.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}